A primary goal of the clinical trials efforts of UPCI is to design, implement and analyze innovative, investigator-initiated pilot and phase 1 clinical trials. The development, initiation, implementation and completion of UPCI investigational studies receive substantial and essential support from UPCI Clinical Research Services (CRS). In 2008, 349 of the 1158 total UPCI patients (30%) participating in interventional clinical trials were entered onto institutional studies initiated by UPCI investigators. These investigatorinitiated trials focus on translational research and involve investigators from all of the translational and disease-specific programs of UPCI. Protocol-Specific Research Support has been instrumental in enabling several of these trials. Review of trials supported in the last grant cycle shows that the many PSRS supported trials advanced to the point of support by other mechanisms and/or publication of results. Requests for PSRS support of novel pilot or innovative phase I clinical trials are made by the PI at the time of submission of the trial to the Protocol Review Committee (PRC). Trials are evaluated for innovation and novelty, as well as availability of other sources of support, at the time of PRC submission. Trials with potential to be supported by PSRS funds are forwarded to the Associate Director of Clinical Investigation who makes recommendations to the Director of UPCI for final approval. Funds are used to support the effort of expert research nurses, termed Clinical Research coordinators, who can assist investigators with all aspects of trial implementation and execution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-25
Application #
8519358
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
25
Fiscal Year
2013
Total Cost
$129,041
Indirect Cost
$69,737
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Ander, Stephanie E; Rudzki, Elizabeth N; Arora, Nitin et al. (2018) Human Placental Syncytiotrophoblasts Restrict Toxoplasma gondii Attachment and Replication and Respond to Infection by Producing Immunomodulatory Chemokines. MBio 9:
Hartmaier, R J; Trabucco, S E; Priedigkeit, N et al. (2018) Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol 29:872-880
Palliyaguru, Dushani L; Yuan, Jian-Min; Kensler, Thomas W et al. (2018) Isothiocyanates: Translating the Power of Plants to People. Mol Nutr Food Res 62:e1700965
Yoon, Joo Heung; Nouraie, Mehdi; Chen, Xiaoping et al. (2018) Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease - analysis of institutional and population data. Respir Res 19:195
Nikiforova, Marina N; Mercurio, Stephanie; Wald, Abigail I et al. (2018) Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer 124:1682-1690
Steel, Jennifer L; Terhorst, Lauren; Collins, Kevin P et al. (2018) Prospective Analyses of Cytokine Mediation of Sleep and Survival in the Context of Advanced Cancer. Psychosom Med 80:483-491
Luthra, Soumya; Chandran, Uma; Diergaarde, Brenda et al. (2018) Expression of reactive species related genes is associated with patient survival in luminal B breast cancer. Free Radic Biol Med 120:170-180
Saydmohammed, Manush; Tsang, Michael (2018) High-Throughput Automated Chemical Screens in Zebrafish. Methods Mol Biol 1683:383-393
Steinman, Justin; Epperly, Michael; Hou, Wen et al. (2018) Improved Total-Body Irradiation Survival by Delivery of Two Radiation Mitigators that Target Distinct Cell Death Pathways. Radiat Res 189:68-83
Yockey, Laura J; Jurado, Kellie A; Arora, Nitin et al. (2018) Type I interferons instigate fetal demise after Zika virus infection. Sci Immunol 3:

Showing the most recent 10 out of 1187 publications